WU 377

Official Title

Inventiva S.A. - 337HNAS20011 / IVPF2F3F-F2F3LF, A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with noncirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis (NATiV3) (Pro00053976)

Study Details

The purpose of the study is to look at a study drug for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH).

Principal Investigator

Dr. Kevin Korenblat

IRB Number



1. Participants must be age 18 or older
2. Participants must have diagnosed non-cirrhotic non-alcoholic steatohepatitis (NASH)
3. Participants must not have hepatitis B or hepatitis C

Volunteer Information

For more information about this study, contact Volunteer for Health at: